Clearside Biomedical Inc Total Assets
Clearside Biomedical Inc total assets. Based on the latest financial reports, Clearside Biomedical Inc (CLSD) holds total assets worth $11.64 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Clearside Biomedical Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Clearside Biomedical Inc (2012–2024)
Total assets of Clearside Biomedical Inc from 2012 to 2024. This chart illustrates how Clearside Biomedical Inc's total assets have evolved over time, based on quarterly financial data. See latest Clearside Biomedical Inc stock price today for real-time trading data and today's change.
Clearside Biomedical Inc - Asset Composition Analysis
Clearside Biomedical Inc Total Assets Breakdown (December 2024)
Clearside Biomedical Inc total assets breakdown as of December 2024. Clearside Biomedical Inc's total assets of $11.64 Million consist of 84.7% current assets and 15.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.7% |
| Accounts Receivable | $507.00K | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CLSD net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clearside Biomedical Inc's current assets represent 84.7% of total assets in 2024, a decrease from 93.1% in 2012.
- Cash Position: Cash and equivalents constituted 79.7% of total assets in 2024, down from 90.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 2.0% of total assets.
Clearside Biomedical Inc Competitors by Total Assets
Key competitors of Clearside Biomedical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Clearside Biomedical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.98 | 4.49 | 1.82 |
| Quick Ratio | 2.98 | 4.49 | 1.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.48 Million | $19.52 Million | $8.18 Million |
Clearside Biomedical Inc - Advanced Valuation Insights
This section examines the relationship between Clearside Biomedical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.93 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -26.1% |
| Total Assets | $25.13 Million |
| Market Capitalization | $2.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Clearside Biomedical Inc's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Clearside Biomedical Inc's assets decreased by 26.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clearside Biomedical Inc (2012–2024)
The table below shows the annual total assets of Clearside Biomedical Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $25.13 Million | -26.14% |
| 2023-12-31 | $34.02 Million | -33.69% |
| 2022-12-31 | $51.30 Million | +19.58% |
| 2021-12-31 | $42.90 Million | +122.04% |
| 2020-12-31 | $19.32 Million | -27.84% |
| 2019-12-31 | $26.78 Million | -39.31% |
| 2018-12-31 | $44.12 Million | +8.96% |
| 2017-12-31 | $40.49 Million | -52.26% |
| 2016-12-31 | $84.81 Million | +302.82% |
| 2015-12-31 | $21.05 Million | +104.44% |
| 2014-12-31 | $10.30 Million | +381.94% |
| 2013-12-31 | $2.14 Million | +125.42% |
| 2012-12-31 | $948.00K | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more